ReviewMolecular nutrition & food research2025
Angiogenesis as a Therapeutic Target of (Poly)phenols: Tackling Cancer and Vascular-Related Complications.
Review in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Solvent-Guided Fractionation of GreenPlants (Basel, Switzerland) · 2026Article
- Depression and breast cancer: research progress and prospects from an interdisciplinary perspective.Frontiers in immunology · 2026Review
- MicroencapsulatedFrontiers in veterinary science · 2026Article
- LncRNA MEG8 promotes deep vein thrombosis by sponging miR-296-5p to regulate human umbilical vein endothelial cells.Hereditas · 2025Article
- Angiogenesis as a Therapeutic Target of (Poly)phenols: Tackling Cancer and Vascular-Related Complications.Molecular nutrition & food research · 2025Review
- Vulnerable plaques in atherosclerosis: focus on angiogenesis-associated phenotypic crosstalk.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Targeting angiogenesis as a strategy for treating cancer or vascular-associated complications is an inspiring field for many investigators. An active area within this discipline is the search for agents capable of modulating angiogenesis in order to ameliorate its structural and functional abnormalities associated with these diseases. (Poly)phenols are a broad group of molecules, many of which fall within the category of natural compounds with therapeutic potential. These potential medicinal effects have launched a considerable number of studies investigating the pro- and(or) anti-angiogenic properties of (poly)phenols in different (patho)physiological settings. The purpose of this review is to summarize the current evidence of the role of (poly)phenols in modulating angiogenesis. This review will guide the reader through preclinical and human investigations describing the pro- and anti-angiogenic effects of these compounds in different pathophysiological context, the cellular and molecular mechanisms associated, the key points in the design and evaluation of the effects described, and suggest new approaches to be considered in future studies to overcome the current limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.